Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure

Circulation Journal

Volumn 66, Issue 6, 2002, Pages 600-604

  Shiga, Tsuyoshi ^a   Wakaumi, Michi ^a   Imai, Taku ^a   Suzuki, Tsuyoshi ^a   Hosaka, Fumitaka ^a   Yamada, Yuichiro ^a   Matsuda, Naoki ^a   Shoda, Morio ^a   Sugiura, Ryo ^a   Hagiwara, Nobuhisa ^a   Kasanuki, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Amiodarone; Antiarrhythmic drugs; Atrial fibrillation; Atrial flutter; Heart failure

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DOFETILIDE;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ETHNIC GROUP; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HOSPITALIZATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; RACE DIFFERENCE; RETROSPECTIVE STUDY; SINUS RHYTHM;

EID: 0036299909     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.66.600     Document Type: Article

References (36)

1. Improving survival for patients with atrial fibrillation and advanced heart failure
2. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study
3. Management of atrial fibrillation in the setting of heart failure
4. Heart failure and atrial fibrillation: Current concepts and controversies
5. Predictors of thromboembolism in atrial fibrillation
6. Prognostic significance of atrial fibrillation in advanced heart failure: A study of 390 patients
7. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Investigators
8. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials
9. Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility
10. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia
11. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observation from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT)
12. Randomised trial of low-dose amiodarone in severe congestive heart failure
13. Can antiarrhythmic drugs survive survival trials?
14. Management of atrial fibrillation: Therapeutic options and clinical decisions
15. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
16. Classification of atrial fibrillation
17. Paroxysmal atrial fibrillation. A need for classification
18. Progression from hypertrophic obstructive cardiomyopathy to typical dilated cardiomyopathy-like feature in the end stage
19. Implications of left ventricular remodeling in hypertrophic cardiomyopathy
20. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure
21. Prevalence and clinical characteristics of patients with atrial fibrillation: Analysis of 20,000 cases in Japan
22. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium
23. Amiodarone for refractory atrial fibrillation
24. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias
25. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy
26. Amiodarone in the management of refractory atrial fibrillation
27. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter
28. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter
29. Low-dose amiodarone for atrial fibrillation
30. Amiodarone to prevent recurrence of atrial fibrillation
31. Distribution of patients' paroxysmal atrial tachyarrhthmia episodes: Implication for detection of treatment efficacy
32. Sudden unexpected death in patients with congestive heart failure: A second frontier
33. Cardiac failure and sudden death in the Framingham study
34. Tarantula peptide inhibits atrial fibrillation: A peptide from spider venom can prevent the heartbeat from losing its rhythm
35. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation
36. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias